DUBLIN, Feb. 8, 2019 /PRNewswire/ --
The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018" report has been added to ResearchAndMarkets.com's offering.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2012 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds?
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals
Chapter 3 - Preclinical stage deal strategies and structure
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
126.96.36.199. Discovery and preclinical stage partnering case studies
188.8.131.52.a. Case study: LEO Pharma - 4SC
184.108.40.206.b. Case study: Heptares Therapeutics - Cubist
220.127.116.11.c. Case study: Incyte - Agenus Bio
18.104.22.168.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
22.214.171.124. Clinical stage partnering case studies
126.96.36.199.a. Case study: Servier - GeNeuro
188.8.131.52.b. Case study: Teva - Xenon Pharmaceuticals
184.108.40.206.c. Case study: AstraZeneca - Ardelyx
220.127.116.11.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. - Tesaro
3.6.1.b. Case study : Marina Biotech - Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics - ThromboGenics
3.7.1.b. Case study: Pfizer - InSite Vision
Chapter 4 - Preclinical stage partnering payment strategies
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
18.104.22.168. Conditionality of upfront payments
4.3.4. Convertible loans
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
22.214.171.124. Issues affecting royalty rates
126.96.36.199. Royalties on combination products
188.8.131.52.a. Case study: Scripps Research Institute-Cyanotech
184.108.40.206. Guaranteed minimum/maximum annual payments
220.127.116.11. Royalty stacking
18.104.22.168. Royalties and supply/purchase contracts
4.3.11. Option payments
Chapter 5 - Trends in preclinical stage deal making
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2012
Chapter 6 - Payment terms for preclinical stage partnering
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates
Chapter 7 - Leading preclinical stage deals
7.2. Top preclinical stage deals by value
Chapter 8 - Top 50 most active preclinical stage dealmakers
8.2. Top 50 most active preclinical stage dealmakers
Chapter 9 - Preclinical stage partnering contracts directory
9.2. Preclinical stage deals with contracts 2012 to 2018
Chapter 10 - Preclinical stage deal making by development stage
10.2. Deals by preclinical stage
Appendix 1 - Preclinical stage dealmaking by companies A-Z
Appendix 2 - Preclinical stage dealmaking by industry sector
Appendix 3 - Preclinical stage dealmaking by stage of development
Appendix 4 - Preclinical stage dealmaking by therapy area
Appendix 5 - Preclinical stage dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/research/rbklrg/global?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets